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The effects of diazepam and Ro 15-1788 were assessed upon responses of mouse spinal cord (SC) 
neurons in cell culture to the amino ac ) neurotransmitters 4-aminobutyric acid (GABA) and S-glutamic 
acid. Diazepam (100 nM) enhanced GABA responses by 65 ± 3% (I 13 cells), while Ro 15-1788 (100 nM) 
failed to alter GABA responses but reduced their enhancement by diazepam. Higher Ro 15-1788 concen- 
trations (I ttM or 10 ~tM) enhanced GABA responses to a moderate extent, while blocking further 
enhancement of GABA by diazepam. Neither diazepam nor Ro 15-1788 affected glutamate responses or 
resting membrane potential or conductance of spinal cord neurons. These results provide elec- 
trophysiological support for partial agonist, rather than pure antagonist, activity of Ro 15-1788. 
The imidazobenzodiazepine Ro 15-1788 (ethyl-8-fluoro-5,6-dihydro-5-methyi-6- 
oxo-4H-imidazo[ 1,5-al[l,4lbenzodiazepine-3-carboxylate) is a potent displacer of 
benzodiazepine (BZ) binding [6] and has been shown to antagonize the behavioral 
and electrophysiological actions of diazepam [I, 6, 12, 18] but not anticonvulsants 
which did not bind to BZ receptors [6. 12, 18]. Low concentrations of  Ro 15-1788 
blocked the in vitro enhancement by diazepam of [3HIGABA or [3Hlmuscimol bin- 
ding to rat brain membranes [8, 17]. 
While initial studies in rodents and humans failed to reveal any intrinsic activity 
of Ro 15-1788 [4, 6], subsequent behavioral studies have demonstrated apparent 
partial agonist activity. At high doses, Ro 15-1788 reduced the convulsant activity 
of pentylenetetrazole, bicuculline and Ro 5-3663 [5, 12, 19] and, like diazepam, Ro 
15-1788 antagonized the development of amygdaloid kindled seizures in rats [1, 15]. 
Using drug discrimination techniques, animals generalized the cue for the BZ 
agonist chlorazepate to Ro 15-1788 [3]. These behavioral results, while suggesting 
that Ro 15-1788 has BZ-like activity, do not necessarily confirm that such activity 
arises from an agonistic effect at BZ receptors. 
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We have investigated the effects of Ro 15-1788 upon GABA responses on mouse 
spinal cord (SC) neurons in cell culture and the enhancement of such responses by 
di,Jepam. We report that low concentrations of Ro 15-1788 (100 nM) antagonized 
diazepam enhancement of GABA responses, while higher concentrations (l ~M and 
10 ~M) enhanced GABA responses, suggesting that Ro 15-1788 is a partial agonist 
at BZ receptors. 
Cell cultures were prepared from SCs with attached dorsal root ganglia from 
12-14-day-old mouse embryos, as described earlier [11, 141, and SC neurons (5-8 
weeks in vitro) were penetrated on the modified stage of  an inverted phase-contrast 
microscope, using high resistance (25-40 MO) glass micropipettes filled with either 
4 M potassium acetate (KAc) or 3 M potassium chloride (KCI). Cultures were bathed 
in a phosphate-buffered saline (composition in raM: NaCI 143.4, KCI 4.2, CaCI2 
0.9, MgCl2 I0.0 and glucose 5.6 in 9.5 mM sodium phosphate buffer at pH 
7.35-7.40), and maintained at 33-34°C. Using a conventional bridge circuit, 
simultaneous current injection and membrane potential measurement were made 
with a single recording micropipette; data were recorded on a 6-channel Gould 
polygraph. 
GABA (0.5 M, pH 3.2) or S-glutamate (0.5 M, pH 10.0) were applied ion- 
tophoretically using 400 ms rectangular current pulses ( + 0.5 to + 20 nA for GABA, 
- 5 to - 8 0  nA for S-glutamate) at 4 s intervals. Diazepam, Ro 15-1788 or vehicle 
(0.1°70 or less dimethylsulfoxide) were applied by miniperfusion (0.2 psi, 30 s) from 
a pipette 15-100 #m from the cell soma. Medium containing vehicle only did not 
alter responses to GABA or S-glutamate. GABA responses (KCI recordings) of 6-9 
mV amplitude were evoked following membrane hyperpolarization to - 80 to - 90 
mV, and glutamate responses (KAc recordings) of similar amplitude obtained near 
resting membrane potential ( -  60 to - 70 mV) were used for assessment of drug ac- 
tions. Data were accepted only if the amino acid responses returned to control levels 
within 5 rain following removal of the drug-containing pipette from the vicinity of 
the cell under study. Results are expressed as mean + standard error of the mean. 
When KAc recording micropipettes are used, application of GABA to SC neurons 
produces membrane hyperpolarization and an increase in membrane conductance 
[ ! 1 ]. Use of KCi-containing recording micropipettes allows chloride ions to enter the 
cell, changing the equilibrium potential for chloride ions from about - 6 5  mV to 
- 2 0  mV, and GABA responses become depolarizing [11]. 
GABA responses were enhanced (65.0 +_ 3.007o) over control by 100 nM diazepam 
(n = 113 cells) in a reversible fashion (Fig. IAI), and responses to S-glutamate were 
unaffected by 1 ~M diazepam (responses 98.9 +_ 1.0070 control, 10 cells, Fig. IA2), 
confirming previous studies demonstrating concentration-dependent enhancement 
of GABA responses by BZs in cultured avian and mouse SC and mouse cortical 
neurons [2, 9, 10, 20]. Diazepam (0.1 nM-10 #M) did not alter membrane potential 
or conductance. 
Ro 15-1788 (100 nM) failed to alter GABA responses, while inhibiting (by 28.9 
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+_ 7.0~o, P<0.01,  Student's t-test) enhancement of GABA responses by 100 nM 
diazepam (Fig. 2). At 1 ~,M, Ro 15-1788 reversibly enhanced GABA responses by 
more than 10% in 14of 15 cells studied (mean enhancement 21.9 ± 2.9%, P<0.001 
from control; Figs. IA3, IB), but did not alter S-glutamate responses (responses 
101.6 ± 0.6~o control, 6 cells; Fig. IA4). At 1 pM, Ro 15-1788 al~o abolished fur- 
ther enhancement of responses by diazepam (Figs. I B and 2). Similar effects on 
basal and diazepam-enhanced GABA responses were seen with 10 pM Ro 15-1788, 
and at this concentration the enhancement of GABA responses by Ro 15-1788 was 
no greater than that observed at 1 pM Ro 15-1788 (Fig. 2). This would suggest that 
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Fig. 1. Effects of diazepam and Ro 15-1788 on amino acid responses of mouse SC neurons in culture. 
AI: effects of diazepam (10- 7 M) on GABA responses (membrane potential (MP) - - 80 mV). A2: ef- 
fects of diazepam (10-6 M) on glutamate responses (MP = -71  mV). A3, 4: effects of Ro 15-1788 (10-6 
M) on GABA (MP - -75  mV) and glutamate (MP - - 7 5  mV) responses. B: blockade of diazepam 
(100 nM) enhancement of GABA responses by Ro 15-1788 (10 -6 M) (MP = - 8 0  mV). C: effects of 
/~CCMe (10- 5 M, CI, MP = - 90 mV) and ~CCEt (10- 5 M, C2, MP - - 90 mV) on GABA responses. 
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the agonistic action of Ro 15-1788 is indeed 'partial' in nature. Ro 15-1788 (0.1 
/~M-10/~M) did not alter membrane potential or conductance. Enhancement of 
GABA but not S-glutamate responses with absence of direct membrane actions sug- 
gests some selectivity in the effects of these BZs. In contrast, another anticonvul- 
sant, phenobarbital, has been shown to inhibit S-glutamate responses and to pro- 
duce membrane hyperpolarization by increasing chloride conductance, a 
GABAmimetic action [10]. Other BZ antagonists O-carboline-3-carboxylic acid 
methyl ester (//CCMe) and the ethyl ester (~CCEt) [7, 12] failed to affect GABA 
responses at 10 ~M (Fig. ICI, IC2) ~CCMe GABA responses 106.4 + 3.4% con- 
trol, 6 cells;/3CCEt GABA responses 101.9 +_ 3.9% control, 8 cells). Thus, not all 
compounds with BZ antagonist activity exhibit agonist activity at high 
concentrations. 
Ro 15-1788 has been demonstrated to block diazepam enhancement of GABA ef- 
fects in cat SC in vivo and isolated rat superior cervical ganglion [12, 13]. In the 
latter preparation very high Ro 15-1788 concentrations (167 #M and greater) 
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Fig. 2. Enhancement of GABA responses by diazepam and Ro 15-1788. Data shown are from 5-15 cells 
for each drug or combination. The effects of 100 nM diazepam, the particular Ro 15-1788 concentration 
studied and the Ro 15-1788-diazepam combination were examined on each cell studied, with 2-3 cycles 
of application of each drug or combination. By Student's t-test: empty stars P<0.02,  significant dif- 
ference from 100 nM c!iazepam; filled stars P<0.01,  significant difference from vehicle alone (0.1070 
dimethylsulfoxide in buffer, hatched bars). Drug concentrations shown on the figure are logarithm 
molar. 
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Neurochemical studies have shown a potent antagonism of diazepam-enhanced 
GABA binding by Ro 15-1788 (IC5o = 5 nM) but have not revealed enhancement 
of GABA binding [8, 17]. These assays were performed at 2°C; since the potency 
of diazepam as an enhancer o f  GABA binding increases severalfold at 25°C [16], 
it may be possible that high concentrations of Ro 15-1788 would enhance GABA 
binding upon assay at physiological temperature. 
A recent study [7] has examined the relationship between in vivo receptor oc- 
cupancy by various BZ receptor ligands and their activity against audiogenic 
seizures in DBA/2 mice. Ro 15-1788, but not 0CCMe or 0CCEt, was found to have 
anticonvulsant activity. Further, the doses required for the anticonvulsant activity 
of Ro 15-1788 were some 150-fold higher than for diazepam. Whereas classical BZ 
agonists had anticonvulsant activity in this model at low receptor occupancy 
(< 10~/e), almost complete occupancy by Ro 15-1788 was required for its anticonvul- 
sant activity. These results, together with the differing concentration-dependencies 
of GABA enhancement by diazepam and Ro 15-1788, suggest that different levels 
of receptor occupancy by the two compounds may be required for the enhancement 
of GABA receptor affinity. 
The partial agonist activity of Ro 15-1788 at high doses or concentrations should 
be taken into account when the compound is used experimentally and clinically. Ro 
15-1788 has been proposed as combination therapy to counteract the sedative effects 
of the antischistosomal BZ 3-methylclonazepam [6] and may be useful in BZ over- 
dose cases. While Ro 15-1788 lacks sedative activity in man at doses of 600 rag/day 
and lower [4], higher doses could possibly cause sedation or tolerance. 
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